Trial · NCT06855108
Caffeine for Hypoxic Ischemic Encephalopathy
NCT06855108, Phase 3, Recruiting, NICHD Global Network for Women's and Children's Health
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Caffeine for Hypoxic Ischemic Encephalopathy. Trials, record NCT06855108. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT06855108
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Caffeine for Hypoxic Ischemic Encephalopathy
- NCT number
- NCT06855108
- Status
- Recruiting
- Phases
- Phase 3
- Enrollment
- 830 participants, estimated
- Lead sponsor
- NICHD Global Network for Women's and Children's Health
- Conditions
- Hypoxic Ischemic Encephalopathy (HIE)
- Interventions
- Caffeine citrate oral solution, Oral placebo solution
- First posted
- 2025-03-03
- Last updated
- 2026-06-24
Source ClinicalTrials.gov
Registered outcomes21
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Composite outcome, defined by the occurrence of any of the following: | 18-22 months | All-cause infant mortality or moderate to severe neurodevelopmental impairment |
| Secondary | Secondary composite outcome, defined by the occurrence of any of the following: | 18-22 months | All-cause infant mortality or severe neurodevelopmental impairment |
| Secondary | All-cause neonatal mortality | 28 days after delivery | Death from any cause to 28 days after delivery |
| Secondary | All-cause infant mortality | 12 months | Death from any cause before first birthday |
| Secondary | All-cause mortality | 18 months | Death from any cause |
| Secondary | Time to all-cause mortality | 18-22 months | Timespan from randomization to death from any cause |
| Secondary | Severe neurodevelopmental impairment | 18-22 months | |
| Secondary | Moderate neurodevelopmental impairment | 18-22 months | |
| Secondary | Composite cognitive, language, and motor scores on the Bayley Scales of Infant and Toddler Development-Fourth Edition | 18-22 months | Cognitive Scale on the Bayley Scales of Infant and Toddler Development - Fourth Edition \- Scale ranges from 55-145 such that higher scores indicate a better cognitive outcome. Language Scale on the Bayley Scales of Infant and Toddler Development - Fourth Edition - Scale ranges from 45-155 such that higher scores indicate a better language outcome. Motor Scale on the Bayley Scales of Infant and Toddler Development - Fourth Edition \- Scale ranges from 45-155 such that higher scores indicate a better motor outcome. |
| Secondary | Hammersmith Infant Neurological Exam score | 6 months | Ranges from 0 to 78 where higher scores indicate a better neurological outcome. |
1 to 10 of 21Source ClinicalTrials.gov
See all 21 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT06855108
GET https://conductscience.org/api/trials/v1/NCT06855108/registered?page=2